Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States

BACKGROUND: The national Comprehensive Cancer Network has suggested pembrolizumab as a second-line therapy for esophageal squamous cell carcinoma (ESCC) patients with a programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 10. However, despite the increased survival rate associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jia, Ye, Zhuomiao, Xu, Zhe, Hao, Zhinan, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780281/
https://www.ncbi.nlm.nih.gov/pubmed/36568792
http://dx.doi.org/10.3389/fpubh.2022.941738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780281/
https://www.ncbi.nlm.nih.gov/pubmed/36568792
http://dx.doi.org/10.3389/fpubh.2022.941738

Ejemplares similares